StreetInsider.com News Articles

Form 8-K INTENSITY THERAPEUTICS, For: Mar 05

Fri, 06 Mar 2026 08:05:00 +0000

si-local-file:///var/storage/secattach/20260306/26122416.html

Form 8-K INTENSITY THERAPEUTICS, For: Mar 05

Fri, 06 Mar 2026 08:05:00 +0000

si-local-file:///var/storage/secattach/20260306/26122416.html

Intensity Therapeutics regains Nasdaq compliance with minimum bid price

Fri, 06 Mar 2026 07:47:16 +0000

Intensity Therapeutics Inc. (NASDAQ: INTS) received formal notice from Nasdaq that it has regained compliance with the exchange's minimum bid price requirement of $1.00 per share.

The biotechnology company's common stock maintained a closing bid price at or above $1.00 for 10 consecutive business days from February 19 through March 4, 2026, according to the company's statement. Nasdaq confirmed the compliance and closed the matter.

Intensity Therapeutics develops intratumoral cancer therapies using proprietary non-covalent conjugation technology. The company has completed two clinical studies with over 200 patients using its drug candidate INT230-6.

The company currently operates multiple clinical trials including a Phase 3

Intensity Therapeutics regains Nasdaq compliance with minimum bid price

Fri, 06 Mar 2026 07:47:16 +0000

Intensity Therapeutics Inc. (NASDAQ: INTS) received formal notice from Nasdaq that it has regained compliance with the exchange's minimum bid price requirement of $1.00 per share.

The company currently operates multiple clinical trials including a Phase 3

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Fri, 06 Mar 2026 07:47:00 +0000

SHELTON, Conn., March 6, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that it has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Fri, 06 Mar 2026 07:47:00 +0000

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Fri, 06 Mar 2026 07:47:00 +0000

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Fri, 06 Mar 2026 07:47:00 +0000

Form 8-K INTENSITY THERAPEUTICS, For: Mar 05

Thu, 05 Mar 2026 08:07:00 +0000

si-local-file:///var/storage/secattach/20260305/26115534.html

Form 8-K INTENSITY THERAPEUTICS, For: Mar 05

Thu, 05 Mar 2026 08:07:00 +0000

si-local-file:///var/storage/secattach/20260305/26115534.html